BrainChild Bio secures $116M for childhood brain cancer CAR T therapy
Seattle-based BrainChild Bio has raised $116 million to develop CAR T cell therapy for DIPG, a rare pediatric brain cancer. The company’s work builds on research from Seattle Children’s and targets additional brain tumors with similar treatments.
Sources: msn.com
“The funding underscores growing investor interest in high-risk, high-reward pediatric oncology therapies, despite limited commercial returns.”
What it means
CAR T therapies have shown promise in blood cancers but face challenges in solid tumors like DIPG due to the blood-brain barrier. BrainChild’s approach could signal a shift in focus toward pediatric applications, where clinical trials are scarce. Success here may hinge on regulatory incentives for rare diseases, though timelines remain uncertain.
Read the original reporting
This is a short summary. The outlets below did the reporting.
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.